黑种草油补充治疗轻症COVID-19:随机对照临床试验方案结构摘要
该方案旨在研究黑种草油(NS)对轻症COVID-19患者的潜在疗效,采用前瞻性、两臂平行、1:1随机、开放标签、对照的II期探索性临床试验,纳入PCR确诊的轻症成人患者,干预组口服NS油500mg软胶囊每日两次共10天加标准治疗,对照组仅标准治疗,主要结局为随机后14天内临床康复比例。
要点
- 本文为试验方案摘要,非结果报告,旨在评估NS油对轻症COVID-19的疗效。
- 干预为NS油500mg软胶囊口服每日两次共10天联合标准治疗。
- 主要结局为随机后14天内临床康复(连续3天无症状)的患者比例。
核心结论
- 该方案旨在评估黑种草油补充治疗对轻症COVID-19患者结局的潜在疗效。
研究设计与样本
- 前瞻性、两臂平行、1:1随机、开放标签、对照的II期探索性临床试验。
- 计划随机最多200例符合标准的轻症COVID-19成人患者。
- 入组患者来自沙特阿拉伯吉达King Abdulaziz大学医院。
关键数值与推荐
- 干预组:黑种草油(MARNYS® Cuminmar)500 mg软胶囊,口服每日两次,共10天,联合标准治疗(退热、止咳)。
- 对照组:仅标准治疗。
- 主要结局:随机后14天内临床康复(定义为连续3天无症状)的患者比例。
- 随机化采用计算机生成方案(随机排列区组大小为10),通过http://www.randomization.com生成。
- 盲法:无盲法。
局限性
- 开放标签设计,无盲法。
- 探索性II期试验,样本量有限。
- 方案版本1截至2020年7月14日,计划完成日期为2020年12月31日。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
OBJECTIVES: To investigate the potential efficacy of Nigella sativa (NS) oil supplementation on the outcomes of patients with mild Coronavirus Disease 2019 (COVID-19). TRIAL DESIGN: Prospective, two-arm, parallel-group, randomised (1:1 allocation ratio), open-label, controlled, exploratory phase II clinical trial of oral NS oil in patients with mild COVID-19. PARTICIPANTS: Inclusion Criteria: - Patients with mild COVID19 (defined as upper respiratory tract infection symptoms in the absence of clinical or radiological signs of pneumonia). - Adult (18 - 65 years old). - Written informed consent by the patient (or legally authorized representative) prior to initiation of any study procedures. - All patients should understand and agree to comply with planned study procedures. - Polymerase chain reaction (PCR)-confirmed infection with Severe Acute Respiratory Syndrome Coronavirus-2 (SARS-CoV-2) from throat swab. EXCLUSION CRITERIA: - Patients with pneumonia or severe illness requiring admission to intensive care unit. - Severe chronic kidney disease (i.e. estimated glomerular filtration rate [eGFR] < 30 mL / min ) or end stage renal disease requiring dialysis - Severe chronic liver disease (Alanine transaminase [AlT] or Aspartate transaminase [AST] > 5 times the upper limit of normal). - Pregnancy or breast feeding. - Anticipated transfer within 72 hours to another hospital that is not a study site. - Allergy to the study medication The trial is currently conducted on patients recruited from King Abdulaziz University Hospital, Jeddah, Saudi Arabia. INTERVENTION AND COMPARATOR: Intervention group: Nigella sativa oil (MARNYS® Cuminmar) 500 mg softgel capsules, one capsule orally twice daily for 10 days plus standard of care treatment (antipyretic, antitussive). Comparator group: standard of care treatment. MAIN OUTCOMES: Proportion of patients who clinically recovered (defined as 3 days of no symptoms) within 14 days after randomisation. RANDOMISATION: Patients will be randomly assigned to treatment or control groups in a 1:1 ratio using a computer-generated randomization scheme (Random permuted blocks of 10) developed using the web-based program: http://www.randomization.com . BLINDING (MASKING): No blinding. NUMBERS TO BE RANDOMISED (SAMPLE SIZE): Up to 200 eligible patients will be randomly assigned to either treatment or control groups. TRIAL STATUS: Protocol version 1, as of July 14, 2020. Recruitment was started on May 21, 2020. The intended completion date is December 31, 2020. TRIAL REGISTRATION: ClinicalTrials.gov Identifier: NCT04401202 . Date of trial registration: May 26, 2020. FULL PROTOCOL: The full protocol is attached as an additional file, accessible from the Trials website (Additional file 1). In the interest of expediting dissemination of this material, the familiar formatting has been eliminated; this letter serves as a summary of the key elements of the full protocol.
引用
- Koshak AE, Koshak EA, Mobeireek AF, et al. Nigella sativa supplementation to treat symptomatic mild COVID-19: A structured summary of a protocol for a randomised, controlled, clinical trial. Trials. 2020. PMID: 32771034. doi:10.1186/s13063-020-04647-x
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。